Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3155)
All Articles published online
|
Publishing Process of This Article
|
Oct 15, 2023 (publication date) through Apr 1, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Li D, Gruber SB, Iyer S, Gupta S, Tejani M. Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States. World J Gastrointest Oncol 2023; 15(10): 1796-1806 [PMID: 37969411 DOI: 10.4251/wjgo.v15.i10.1796] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i10/1796.htm |
| Number | Citing Articles |
| 1 |
A. Dalbeni, F. Cattazzo, L. A. Natola, M. Zoncapè, D. Faccincani, B. Stefanini, F. Ravaioli, R. Villani, A. Auriemma, D. Sacerdoti. What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?. Expert Review of Gastroenterology & Hepatology 2025; 19(4): 389 doi: 10.1080/17474124.2025.2476541
|
| 2 |
Xiaomo Xiong, Jeff Jianfei Guo. Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA. PharmacoEconomics 2025; 43(3): 271 doi: 10.1007/s40273-024-01453-0
|